Share on

North America Atopic Dermatitis Market Research Report – Segmented By Treatment Type, Route of Administration, Distribution Channel & Country (US, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2022 to 2027)

Published: January, 2022
ID: 5170
Pages: 145
Formats: report pdf report excel report power bi report ppt

North America Atopic Dermatitis Market Size (2022 to 2027)

The size of the Atopic Dermatitis Market in North America is expected to grow from USD 3.35 billion in 2022 to USD 6.27 billion by 2027, growing at a CAGR of 13.4% from 2022 to 2027. 

Atopic dermatitis is a skin condition that causes inflammation. The severity of the disease varies from one patient to the next. It usually starts in childhood and is primarily limited to the body's flexural surfaces. It is widespread. Eczema is the more frequent name for it. Itching, redness of the skin, cracking, weeping, and other symptoms are all signs of it. It is a chronic illness. The most prevalent causes are low humidity, chilly weather, and seasonal allergies. The type of treatment that should give depends on the pattern of the disease and its severity.

YOY rise in the patient population in North American countries, numerous new product launches, issues with climate change, and a massive pipeline of therapies are a few of the major factors driving the atopic dermatitis market in North America. On the other hand, the market growth is driven by rising skin allergies and chronic illnesses. The severity of atopic dermatitis illnesses varies from patient to patient, depending on the therapeutic modalities used. The rate of growth of the atopic dermatitis treatment market is accelerated by rising healthcare spending and the increased popularity of these treatment techniques due to digital advertisements. In patients with atopic dermatitis, allergies have a crucial influence. When the patient is exposed to things that induce allergic reactions, the condition usually flares up. According to the American College of Allergy, Asthma, and Immunology, it is widespread in newborns and children, accounting for 10-20% of individuals with eczema.

Furthermore, an increasing number of government programs aimed at enhancing the infrastructure of hospitals and clinics with cutting-edge equipment are likely to boost the atopic dermatitis market growth. In addition, an increasing number of patients with various skin ailments, changing climatic conditions, and rising disposable income in both developed and developing countries are likely to increase the market's growth. Moreover, the rise of cutting-edge medical technology and the launch of novel procedures are driving up demand in this market.

The lack of competent individuals in hospitals and clinics and changes in economic strategy have a detrimental impact on the growth rate of the atopic dermatitis market in North America. In addition, the market continues to be challenged by a lack of essential equipment in rural areas. Moreover, the high cost of treatment methods due to enhanced features is slowing the market's growth rate.

This research report on the North America Atopic Dermatitis Market has been segmented and sub-segmented into the following categories

By Treatment Type:

  • Drug Treatment
  • Radiation Treatment

By Route of Administration:

  • Topical
  • Oral

By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • online pharmacies

By Country:

  • US
  • Canada
  • Rest of North America

Geographically, North America is anticipated to lead the atopic dermatitis market worldwide over the forecast period owing to the growing number of product introductions, rising awareness regarding early treatment adoption among the public, and lifestyle modifications. In addition, the lucrative nature of this market in North America is aided by factors such as high treatment awareness among the patient population across the United States and Canada. Furthermore, even though both countries have high healthcare costs, select foundations, such as the PAN Foundation, National Eczema Associations, and various pharmaceutical firms and grants, organize a growing number of campaigns each year.

The U.S atopic dermatitis market dominated the North American market, and it is likely to continue its domination throughout the forecast period. Advanced healthcare infrastructure, early adoption of novel medications, and favorable reimbursement policies contribute to market growth. In addition, the increasing business partnerships between pharmaceutical companies and contract research organizations in emerging markets.


A few of the companies that are playing a notable role in the North American atopic dermatitis market profiled in the report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Novartis International AG, and Pfizer Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample